“Time is of the essence.” There are times when moving quickly in drug development felt like an edge. Now it feels more like table stakes.
Whether it’s pressure from investors, competition in crowded therapeutic areas, or simply the cost of holding a program too long in development, timelines have tightened across the board. What used to be acceptable pacing, even a few years ago, now feels slow.
But the challenge is that speed isn’t just about working faster. It’s about removing the points in development where things tend to stall, and more often - those points show up in formulation and manufacturing at a later stage.
Where Timelines Actually Break Down
If you talk to enough development teams, a pattern starts to emerge. Early work moves quickly. There’s momentum, strong data, and a clear path forward. Then things start to slow.
It might be a formulation from R&D that doesn’t scale the way it was expected to. Or analytical methods that need to be reworked once the process evolves. Sometimes it’s a technology transfer that takes longer than planned because critical details weren’t addressed early on.
Individually, none of these issues seems catastrophic. But collectively, they can add months (or longer) of delays in filing the drug products.
And in today’s environment, that’s not a small delay.
Designing Development With Scale in Mind
One of the more subtle shifts happening right now is the expectation that early decisions need to hold up much further downstream. It’s no longer enough to get something that works in a lab setting. There’s increasing pressure to think about manufacturability much earlier in the process based on robust formulation.
That’s easier said than done.
Formulation strategies that look promising at small scale don’t always translate cleanly. Processes that seem straightforward in development can become complicated under cGMP conditions. And if those gaps aren’t addressed early, they tend to surface at exactly the wrong time with much broader implications.
This is where Ascendia Pharmaceutical Solutions’ approach stands out a bit. Their work tends to start with the assumption that whatever is developed will need to scale, and that influences how formulations are designed from the beginning.
It doesn’t eliminate challenges, but it reduces the number of surprises at later stage.
The Value of Keeping Work Connected
There’s also a practical side to speed that doesn’t get talked about enough, and that’s continuity with workflow and to reduce tech transfer constraints.
When different parts of development are split across multiple vendors, each transition introduces friction. Even with strong communication, there’s always some loss of context and technical know-how. Teams have to master for getting up to speed by revalidating methods, and fixing small inconsistencies that could turn later into larger issues.
Keeping those pieces connected (formulation, analytics, manufacturing) doesn’t just simplify logistics... It shortens the feedback loop. Adjustments can be made faster because the same group is working across stages, rather than passing work back and forth to different groups.
Ascendia Pharmaceutical Solutions has built its model around that idea. It’s not necessarily about offering more services; it’s about making sure the services that matter most are seamless and aren’t disconnected from each other.
Why Complex Modalities Raise the Stakes
All of this becomes more important as the industry leans further into complex therapeutics.
Small molecules with solubility challenges, biologics with stability concerns, RNA-based therapies that depend on delivery systems like lipid nanoparticles, these aren’t edge cases anymore. They’re increasingly common.
And with that complexity comes less room for error. A formulation tweak isn’t always a minor adjustment. It can affect stability, delivery, and ultimately clinical performance.
That’s part of why there’s been so much focus on technologies like nanosizing, microemulsions, amorphous solid dispersions, and lipid-based delivery systems. Not because they’re new, but because they’re becoming necessary to move certain programs forward at all.
Moving Faster Without Cutting Corners
There’s always a tension in development between speed and risk. Move too quickly, and you introduce problems that can come back to haunt later. Move too cautiously, and you lose time you can’t get back.
The goal, ideally, is to move efficiently - making decisions early that don’t need to be undone later.
That’s easier to achieve when formulation, analytical strategy, and manufacturing are aligned from the start, rather than stitched together as the program advances.
What Sponsors Are Really Looking For
At a certain point, most sponsors aren’t just looking for a vendor to execute individual tasks. They’re looking for a partner with the right expertise and capabilities that can help them avoid the common pitfalls, the delays that don’t show up in project plans.
That usually comes down to experience with the types of challenges that aren’t obvious at the outset.
Ascendia Pharmaceutical Solutions’ role in that process is fairly straightforward with the notion of first time right. They focus on the parts of development where complexity tends to create delays, and they try to address those issues early enough to avoid problems later.
It’s not a dramatic shift in how development works. But it’s a practical one, and in the current environment, that’s often what makes the difference.